Auxilium Pharmaceuticals receives approval to sell Testim in Canada

By Elaine Rigoli

Tampa Fla., May 23 - Auxilium Pharmaceuticals, Inc. announced that Health Canada's Therapeutic Products Directorate has granted marketing approval of Testim 1%, its topical testosterone gel, indicated for the treatment of patients with hypogonadism (low testosterone).

The company said Testim is now approved for sale in 15 countries outside the United States.

"The Health Canada approval complements Testim's regulatory approvals in the U.S. and in Europe. We are pleased to expand Testim's global reach to include Canada, the fourth-fastest growing pharmaceutical market in the world," chief executive officer Gerri Henwood said in a news release.

Auxilium Pharmaceuticals, based in Malvern, Pa., is a specialty pharmaceutical company with a focus on developing and marketing products for urology, sexual health and other indications within specialty markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.